In this study published in Cell Reports, FCF-funded researcher Praveen Sethupathy and his team at Cornell University have leveraged a novel genomics technology to uncover therapeutic vulnerabilities in fibrolamellar carcinoma. Collaborators on the study include FCF-funded John Scott and F. Donelson Smith at the University of Washington. The lead author is Tim Dinh, who recently …
April 21st was a red letter day for the fibrolamellar community. A patient at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University, Baltimore, MD received the initial treatment of the first experimental therapy aimed to directly target the primary molecular cause of fibrolamellar carcinoma (FLC)…
The emerging COVID-19 pandemic has created unprecedented global challenges. We know that for individuals with underlying conditions, including cancer, the situation may seem fraught with uncertainty. We urge patients and caregivers to reach out …
A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique chimeric protein …
The Fibrolamellar Cancer Foundation (FCF) is proud to announce The Mark Foundation for Cancer Research has awarded their coveted Aspire Award to Dr. Paul Thomas, St. Jude Children’s Research Hospital for fibrolamellar carcinoma immunotherapy research. The Aspire Award …
The Chan Zuckerberg Initiative (CZI) announced that the Fibrolamellar Cancer Foundation (FCF) is among a select group of patient-led rare disease organizations, including rare cancer foundations, to receive the first CZI Rare As One Network grant…
Big thanks to Jenny Carroll, Jennifer Strickland and all in the FLC community who participated in the 2019 Department of Defense grant reviews. Since liver cancer has been an approved cancer for DOD funding, Fibrolamellar has been awarded over $2 million in support…
FCF Press Release on Rare Disease Day Tuesday October 1, 2019 is Rare Cancer Day. The event this year is especially important because at the Fibrolamellar Cancer Foundation (FCF) we are celebrating ten years of bringing awareness to this disease. We are proud to have contributed nearly $8 million to researching cures and treatments for …
Nearly 80 members of the fibrolamellar scientific community – USA and international- gathered in Greenwich, CT in early November to share their research, discoveries and hopes for curative therapies. Importantly those attending embrace collaboration and data sharing – even if their research is not published …